The Food and Drug Administration recently approved AstraZeneca's (AZN 1.03%) Epanova, adding it to the growing list of omega-3 fish oil drugs that includes GlaxoSmithKline's (GSK 1.60%) Lovaza and Amarin's (AMRN 2.03%) Vascepa.
In the following video, senior biotech specialist Brian Orelli and health-care analyst David Williamson discus the market dynamics for fish oil drugs, which has Lovaza dominating the market even though Vascepa is arguably a better drug.
We'll have to see whether AstraZeneca can use its marketing muscle to succeed where Amarin has failed. Epanova has some advantages because it can be taken just once a day and doesn't have to be taken with food, but it's debatable whether thosae are big enough to get patients to switch.
